| 000 | 01969nam a2200313Ia 4500 | ||
|---|---|---|---|
| 001 | 288234 | ||
| 003 | OCoLC | ||
| 005 | 20160527201727.0 | ||
| 008 | 070810s2007 vau b 000 0 eng d | ||
| 010 | _a2007033206 | ||
| 020 | _a9781570185762 (alk. paper) | ||
| 020 | _a157018576X (alk. paper) | ||
| 035 | _a(OCoLC)237292273 | ||
| 040 | _aPUCPR | ||
| 049 | _acicg | ||
| 050 | 0 | 0 |
_aKF 2915 .P4 _bP495 2007 |
| 245 | 0 | 0 |
_aPharmaceutical law _bregulation of research, development, and marketing _ceditor-in-chief, Michael E. Clark. |
| 260 |
_aArlington, Va _bBureau of National Affairs _cc2007. |
||
| 300 |
_axlvi, 853 p. _c26 cm. |
||
| 500 | _a"American Bar Association, Health Law Section" | ||
| 504 | _aIncludes bibliographical references and index. | ||
| 505 | 0 | _aStatutory and regulatory controls for drug development -- Key federal agencies regulating pharmaceuticals -- Federal regulation of advertising, promotion, and distribution practices -- Potential liability for drug companies, health care providers and insurers: off-label prescribing and internet advertising -- Federal regulation of clinical research -- Avoiding fraud and abuse penalties and sanctions -- Regulation of privacy under hipaa and other privacy laws -- Federal sentencing guidelines and compliance measures -- The FDA approval process for new drugs -- State regulatory schemes for pharmaceuticals and related issues -- Antitrust and intellectual law issues for pharmaceutical companies -- Securities law issues and disclosure considerations for pharmaceutical companies. | |
| 650 | 0 |
_aPharmacy _xLaw and legislation _zUnited States. _2Local _9150493 |
|
| 650 | 0 |
_aDrug development _zUnited States. _2Local _988797 |
|
| 650 | 0 |
_aPharmaceutical Industry _zUnited States. _2Local _9150476 |
|
| 650 | 0 |
_aDrugs _xLaw and legislation _zUnited States. _2Local _988821 |
|
| 700 | 1 |
_aClark, Michael E. _d1956- _2Local _973972 |
|
| 710 | 2 |
_aAmerican Bar Association. _bHealth Law Section. _2Local _952025 |
|
| 999 |
_c208468 _d208468 |
||